Inovio Pharmaceuticals' GAAP loss for 3 months of 2022 was $79.909 million, up 48.1% from $53.968 million in the previous year. Revenue decreased 46.4% to $199,074 thousand compared to $371,12 thousand a year earlier.
Inovio Pharmaceuticals' GAAP loss for 3 months of 2022 was $79.909 million, up 48.1% from $53.968 million in the previous year. Revenue decreased 46.4% to $199,074 thousand compared to $371,12 thousand a year earlier. 
ir.inovio.com
English (US) 